Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Lucentis 10 mg/ml solution for injection, FARICIMAB
Hoffmann-La Roche
Choroidal neovascularization secondary to pathologic myopia
1 trial -
Lucinactant
WINDTREE THERAPEUTICS INC /DE/
Meconium Aspiration
1 trial -
Lumacaftor Plus Ivacaftor Combination
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
1 trial -
Lumacaftor Plus Ivacaftor Combination
Vertex Pharmaceuticals (Australia) Pty.
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria Type 1
1 trial -
Lumasiran
Alnylam Netherlands B.V.
Primary Hyperoxaluria
1 trial -
Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets
The George Institute
Patients with a histological diagnosis of p53abn HREC, treated with curative intent, after surgery (hysterectomy and bilateral salpingooophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases
1 trial -
Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB
AstraZeneca AB
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer
1 trial -
Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7
The George Institute
Unresectable locally advanced and/or metastatic soft-tissue sarcoma
1 trial -
Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets
AstraZeneca AB
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer
1 trial -
MC0518, EVEROLIMUS, MYCOPHENOLIC ACID , ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Steroid refractory Acute Graft versus host Disease
1 trial -
MEDI4736
AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
1 trial -
MEDI4736 Placebo, DURVALUMAB
CERO THERAPEUTICS HOLDINGS, INC.
Completely resected primary stage IB (β₯ 4cm), II and IIIA non-small cell lung cancer patients
1 trial -
MEPOLIZUMAB
GlaxoSmithKline
Hypereosinophilic syndrome (HES)
1 trial -
MESNA, MESNA, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Fludarabine Teva 25 mg/ml concentraat voor oplossing voor injectie of infusie, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Endoxan 1000 mg milteliai injekciniam tirpalui, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cycloph
Iovance Biotherapeutics B.V.
Melanoma
1 trial -
METFORMIN, COLCHICINE, MINOCYCLINE, Placebo tablets are identical to active minocycline tablets and will be relabelled identical to the study drug. Placebo tablets will have the same composition, except for the active substance. (microcrystalline cellulose, magnesium stearate).
Disc Medicine
PASC: post-acute sequelae of SARS-CoV-2 infection
1 trial -
METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE
Pfizer Australia Pty Ltd
Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)
1 trial -
METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE
Pari Pharma GmbH
Cutaneous lupus erythematosus
1 trial -
METHOTREXATE, METHOTREXATE, DESOXIMETASONE, TACROLIMUS, placebo, Acidum folicum LΓ©Δiva 10 mg obalenΓ© tablety, FOLIC ACID
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
moderate to severe atopic dermatitis
1 trial -
METHYLPREDNISOLONE , ACETYLCYSTEINE
The George Institute
Acute Alcoholic hepatitis
1 trial -
METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL
Hoffmann-La Roche
Lupus Nephritis (LN)
1 trial -
METOCLOPRAMIDE , -, SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion, OCTREOTIDE
Novartis Pharmaceuticals
Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
1 trial -
MGL-3196
Madrigal Pharmaceuticals EU Limited
NASH - Nonalcoholic Steatohepatitis
1 trial -
MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet
Madrigal Pharmaceuticals EU Limited
Non-alcoholic Steatohepatitis (NASH) Cirrhosis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources